BTIG:'Phase 3 HERO Update and RYTM PWS Phase 2 Data Read Positively to AARD'
Tweet Send to a Friend
BTIG analyst Jeet Mukherjee reiterated a Buy rating and $26.00 price target on Aardvark Therapeutics Inc (NASDAQ: AARD).The analyst comments ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
